TABLE 3.

Relative effect estimates for all possible pairwise treatment comparisons for overall survival, progression-free survival.

Overall survival, hazard ratio (95% CI)
Pembrolizumb
1.29 (0.88, 1.90)	Camrelizumb
1.27 (0.75, 2.13)	0.98 (0.55, 1.75)	Sintilimab
1.48 (0.93, 2.36)	1.15 (0.67, 1.95)	1.17 (0.62, 2.20)	Sugemalimab
0.81 (0.62, 1.05)	0.63 (0.43, 0.90)	0.64 (0.38, 1.06)	0.55 (0.35, 0.86)	Atezolizumab
0.71 (0.58, 0.87)	0.55 (0.40, 0.76)	0.56 (0.35, 0.90)	0.48 (0.32, 0.73)	0.88 (0.74, 1.04)	Chemotherapy
Progression-free survival, hazard ratio (95% CI)
Pembrolizumb
1.54 (1.15, 2.07)	Camrelizumb
1.08 (0.69, 1.68)	0.70 (0.44, 1.10)	Tislelizumab
1.06 (0.77, 1.45)	0.69 (0.50, 0.95)	0.98 (0.62, 1.56)	Sintilimab
1.73 (1.19, 2.51)	1.12 (0.77, 1.64)	1.61 (1.02, 2.82)	1.64 (1.10, 2.43)	Sugemalimab
0.80 (0.61, 1.06)	0.52 (0.39, 0.69)	0.74 (0.09, 6.02)	0.75 (0.09, 6.16)	0.46 (0.32, 0.67)	Atezolizumab
1.02 (0.12, 8.4)	0.66 (0.46, 1.04)	0.95 (0.54, 1.66)	0.96 (0.61, 1.53)	0.59 (0.35, 0.98)	1.27 (0.82, 1.96)	Toripalimab
0.57 (0.47, 0.70)	0.37 (0.30, 0.46)	0.53 (0.36, 0.79)	0.54 (0.42, 0.69)	0.33 (0.24, 0.45)	0.71 (0.59, 0.85)	0.56 (0.38, 0.83)	Chemotherapy
Serious adverse events, odds ratio (95% CI)
Tislelizumab
1.58 (0.37, 6.80)	Sugemalimab
1.18 (0.26, 5.31)	0.74 (0.18, 3.06)	Sintilimab
1.43 (0.34, 6.09)	0.91 (0.24, 3.47)	1.21 (0.3, 5.07)	Pembrolizumb
1.57 (0.37, 6.89)	0.99 (0.25, 3.91)	1.33 (0.32, 5.71)	1.1 (0.28, 4.31)	Camrelizumb
0.85 (0.39, 1.68)	0.54 (0.14, 2.1)	0.72 (0.18, 3.03)	0.59 (0.15, 2.27)	0.54 (0.14, 2.12)	Atezolizumab
1.75 (0.59, 5.21)	1.11 (0.42, 2.89)	1.49 (0.52, 4.24)	1.22 (0.47, 3.16)	1.12 (0.49, 2.99)	2.06 (0.78, 5.26)	Chemotherapy